SCHEMBL7045368

SCHEMBL7045368

O=C(O)N1CCCN(c2ccc(S(=O)(=O)c3cccc(F)c3)c([N+](=O)[O-])c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 8/20 0.51
LMNA P02545 7/20 0.51
SMN1; SMN2 Q16637 5/20 0.51
NOD2 Q9HC29 2/20 0.51
MAPT P10636 8/20 0.51
ALDH1A1 P00352 7/20 0.51
NPSR1 Q6W5P4 3/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
MAPK1 P28482 2/20 0.47
TNF P01375 1/20 0.47
NOD1 Q9Y239 1/20 0.47
HTR6 P50406 1/20 0.46
TDP1 Q9NUW8 3/20 0.45
PKM P14618 1/20 0.45
RECQL P46063 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
VDR P11473 2/20 0.43
THRA P10827 1/20 0.43
KIF18A Q8NI77 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7045372 1.00 HTT (0.51) HTTLMNASMN1; SMN2NOD2MAPT
SCHEMBL6744352 0.89 MAPT (0.50) HTTLMNASMN1; SMN2NOD2MAPT
SCHEMBL7048761 0.86 KIF18A (0.57) HTTLMNASMN1; SMN2NOD2MAPT
SCHEMBL7048759 0.86 KIF18A (0.57) HTTLMNASMN1; SMN2NOD2MAPT
SCHEMBL7044429 0.85 HTR6 (0.51) HTTLMNASMN1; SMN2MAPTALDH1A1
SCHEMBL6741374 0.82 HTR6 (0.68) SMN1; SMN2MAPTALDH1A1MAPK1HTR6
SCHEMBL7048580 0.81 HTR6 (0.58) HTTLMNASMN1; SMN2MAPTALDH1A1
SCHEMBL22095447 0.76 THRB (0.59) VDRTHRA
SCHEMBL6745785 0.75 KIF18A (0.55) HTTLMNASMN1; SMN2NOD2MAPT
SCHEMBL6744104 0.74 MAPT (0.58) HTTLMNASMN1; SMN2NOD2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030207866-A1 Drugs useful for the treatment of diseases or disorders of the central nervous system. PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed
US-6586592-B2 Labled isotopes of phenyl 4-(1,4-diazepin-1-yl)-2-amino phenyl sulfone derivatives used in nuclear magnetic resonance imaging and positron emission tomography PHARMACIA & UPJOHN COMPANY 2003-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207866-A1 Drugs useful for the treatment of diseases or disorders of the central nervous system. PMP22, NLN, INA HTT 103/4885LMNA 2142/4885SMN1; SMN2 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.